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Summary Wnt genes are transforming to mouse breast epithelium and are hormonally regulated in vivo. To assess their role in another
endocrine-responsive human cancer, the expression of seven Wnt genes (Wnt 2, 3, 4, 5a, 7a, 7b and 1Ob) in normal human endometrium and
endometrial cells, and endometrial carcinoma tissues and cell lines was investigated by ribonuclease protection analysis. Wnt2, 3, 4 and 5a
mRNAs but not Wnt7a, 7b or 10b mRNAs were expressed in primary culture of normal endometrial epithelial (NEE) and stromal (NES) cells.
In contrast, in four endometrial carcinoma cell lines (RL95-2, HEC-1-A, AN3 CA and Ishikawa), Wnt2 and Wnt3 mRNAs were absent. Wnt4
was expressed in only one out offour cell lines (RL95-2), and Wnt5a was much lower. Wnt7a and Wnt7b mRNAs were expressed in three out
of four cell lines (RL95-2, HEC-1-A and Ishikawa). WntlOb mRNA was expressed in RL95-2 and AN3 CA. In fresh tissues, all Wnt genes
apart from WntlOb were expressed in normal endometrium and endometrial carcinoma. Similar to the cell lines, the level of Wnt4 mRNA
expression was significantly higher in the normal endometrium than endometrial carcinoma. Wnt2, 3 and 5a mRNAs were also lower in
endometrial carcinoma compared with normal endometrium. There was no difference in the level of Wnt2, 3, 4 and 5a mRNA expression
between proliferative phase and secretory phase of the menstrual cycle, or between either menstrual phase and the first trimester of
pregnancy. In vitro, progesterone and/or 17,l-oestradiol had no effect on Wnt2, 3, 4, 5a and 7b mRNA expression in NES and all endometrial
carcinoma cell lines. The data indicate that all Wnt genes were expressed in vitro, six out of seven Wnt genes (Wnt 2, 3, 4, 5a, 7a and 7b)
were expressed endogenously in the human endometrium, their mRNA expression was hormonally independent and Wnt4 gene down-
regulation as well as down-regulation of Wnt 2, 3 and 5a may be associated with endometrial carcinoma.
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Wnt genes make up a large family of highly conserved develop-
mental genes. The first member, int-1, was discovered as a
common integration site of mouse mammary tumour virus
(MMTV) in mammary epithelial adenocarcinomas (Nusse and
Varmus, 1992). Int-i exhibits a high homology to the Drosophila
developmental gene wingless that is involved in pattern formation.
The combination of wingless and int-i gives rise to the term Wnt
so that int-I became Wntl and is the first member ofthe Wnt gene
family (Nusse et al, 1991). In the MMTV-induced mouse
mammary carcinoma, two additional Wnt3 and WntlOb genes are
also known to be activated concomitantly with FGF3 and FGF8
genes, respectively, indicating members ofthe Wnt and FGFfami-
lies act co-operatively to induce tumorigenesis (Roelink et al,
1990; Lee et al, 1995). On its own, Wntl is capable of inducing
mammary hyperplasia and carcinoma that are unaffected by
ovariectomy and adrenalatomy in both transgenic male and female
mice (Lin et al, 1992; Edwards et al, 1992). In the presence of
FGF3, the rate of Wntl-induced mouse mammary hyperplasia is
increased indicating the role ofFGFin accelerating tumorigenesis
Received 24 April 1996
Revised 9 September 1996
Accepted 16 October 1996
Correspondence to: AL Harris, Imperial Cancer Research Fund, University of
Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, Headington,
Oxford OX3 9DU, UK
(Kwan et al, 1992). Evidence from the in vitro studies has also
demonstrated the ability of some Wnt genes (Wntl, 2, 3a, 5b, 7a
and 7b) to cause partial transformation in the mouse mammary
epithelial cell line, C57MG (Wong et al, 1994) and Wntl, 6 and 7b
in the mouse embryonic fibroblast cell line, C3H 1OT1/2
(Bradbury et al, 1994). A subset ofthe murine Wnt genes (Wnt2, 4,
Sa, Sb, 6 and 7b) has been found to be expressed differentially in
virginal, pregnant, lactating and involuting mammary tissues
(Gavin et al, 1992; Buhler et al, 1993; Weber-Hall et al, 1994).
Furthermore, Wnt2, Wnt4 and Wnt5b are regulated by ovarian
hormones indicating the role of Wnts in the normal development
ofthe mouse mammary gland.
Homologues of mouse Wnt genes have been isolated in
Drosophila, Xenopus, chicken and humans (Nusse and Varmus,
1992). In humans, there are nine Wnt genes known [Wntl (van
Ooyen et al, 1985), Wnt2 (Wainright et al, 1988), Wnt3 (Roelink et
al, 1993), Wnt5a (Clark et al, 1993; Lejeune et al, 1995), Wnt3a,
Wnt4, Wnt7a and Wnt7b (Huguet et al, 1994), and WntlOb (Bui et
al, 1997a)]. Four Wnt genes (Wnt2, 4, Sa and 7b) are more highly
expressed in human breast carcinomas compared with normal
breast tissues (Huguet et al, 1994; Lejeune et al, 1995).
Additionally, Wnt5a is also up-regulated in lung, colon and
prostate carcinomas and melanomas (Jozzo et al, 1995), Wnt2 is
up-regulated in colon carcinomas (Vider et al, 1996) and Wnt7b is
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up-regulated in superficial bladder carcinomas compared with
normal bladder tissues and invasive bladder carcinomas (Bui et al,
1997b). This accumulating evidence supports the role of Wnt
genes in the development ofhuman malignancy.
In the mouse uterus, Wnt5a is expressed in the uterine
mesenchyme but not in the uterine or vaginal epithelium, and is
required for the induction ofthe homeobox-containing gene, MsxJ,
in Mullerian epithelium. TheMsxJ gene, in turn, plays an important
role in maintaining the adult uterus in a morphogenetic and devel-
opmentally responsive state (Pavlova et al, 1994). The expression
of Wnt genes in the human uterus has not yet been reported.
Therefore, the aim of this study was to examine the expression of
seven Wnt genes in normal human endometrium, primary cultures
ofendometrial cells, endometrial carcinoma tissues and cell lines in
order to evaluate hormonal regulation in the human endometrium
and differential expression in endometrial cancer.
MATERIALS AND METHODS
Primary cells, cell lines, tissue samples and RNA
preparation
The primary normal human endometrial epithelial (NEE) and
stromal (NES) cells were isolated and maintained as described
(Zhang et al, 1995). The human endometrial carcinoma cell lines
were obtained from the American Type Culture Collection,
Bethesda, MD, USA: RL95-2 (CRL 1671), HEC-1-A (HTB 112)
and AN3 CA (HTB 111); and Ishikawa from Dr John White
(Hammersmith Hospital, London, UK). The normal human
endometrium and endometrial carcinoma samples were obtained at
hysterectomy, frozen immediately and stored in liquid nitrogen
until required. The stage of the menstrual cycle of the tissue was
determined from the patient's menstrual history and endometrial
histology (Noyes et al, 1950; Ferenczy, 1987; Buckley and Fox,
1989). Human first trimester decidua was obtained at termination
of pregnancy and stored in liquid nitrogen until required. All the
cells were cultured in Dulbecco's modified Eagle medium
(DMEM) (Imperial Cancer Research Fund Clare Hall Laboratories,
UK) and 10% fetal calf serum (FCS; Globepharm), on plastic
culture plates (Becton Dickinson) at 37°C, 5% carbon dioxide/95%
air, in a humidified incubator. The cells were allowed to reach
confluence before harvest. Total RNA was prepared from tissues
and cells using the acid guanidium thiocyanate-phenol-chloroform
extraction method as described (Chomczynski and Sacchi, 1987),
followed by a 5.7 M caesium chloride separation in polyallomer
tubes (13 x 51mm; Beckman) at 50 000 r.p.m. for 3 h using SW50
or SW55 swing rotor (Beckman) in the L8-80M ultracentrifuge
(Beckman). The RNA pellet was resuspended in 200 tl of sterile
water, treated with RNAase-free DNAase at 37°C for 15 min,
extracted with an equal volume ofphenol, ethanol precipitated with
0.1 x volume ofsodium acetate, pH 5.2, and resuspended in water
to the final concentration of 1 [ig RI-'.
Treatment of cells with progesterone and 17p-oestradiol
Cells were grown to confluence and then allowed to quiesce for
1 week in oestrogen-free medium containing phenol red-free
DMEM/10% dextran-coated charcoal-stripped FCS. Cells were then
treated with fresh oestrogen-free medium containing either
5 x l0-Y Mprogesterone (Sigma) or5 x 10-'°M17p3-oestradiol (Sigma)
for 18 h. Total RNA was harvested from cells as described above.
Riboprobe constructs and ribonuclease (RNAase)
protection analysis
The human Wnt 2, 3, 4, 7a and 7b (Huguet et al, 1994), Wnt5a
(Lejeune et al, 1995), Wnt lOb (Bui et al, 1997b) and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (McCarthy and
Bicknell, 1992) riboprobe constructs have been described. The
linearized plasmid DNA was labelled with a[32P]CTP
(Amersham) to generate antisense riboprobe, which was thenpuri-
fied using the Spin Column according to the manufacturer's
instructions (Boehringer Mannheim). RNAase protection analysis
was performed using standard protocols (Ausubel et al, 1990).
In brief, 10 ,tg oftotal RNA was hybridized to 30 [l ofhybridiza-
tion mix containing 105 c.p.m. of Wnt and 5.0 x 104 c.p.m. of
GAPDH antisense riboprobes at 45°C for 5-12 h. After
RNA-RNA hybridization, RNAase digestion with RNAaseA and
RNAaseT1 was performed at room temperature for 30 min,
followed by treatment with protein K at 37°C for 15 min. The
sample was then extracted with an equal volume of phenol,
precipitated with 0.1 x volume of sodium acetate, pH 5.2, elec-
trophoresed on a 6% polyacrylamide/urea gel and autoradi-
ographed at -70°C with intensifying screens. Yeast total RNA
(Boehringer Mannheim) was used as a negative control. The
protected fragment signals for Wnt and GAPDH were quantified
by laser densitometry using a Bio Image analyser (Millipore). The
level of Wnt mRNA expression was shown as a ratio of
Wnt/GAPDH protected fragment signals.
Statistical analysis
The level of expression of all the Wnts in human endometrial
tissues and endometrial tumours were compared using the Student
unpaired t-test, using the Minitab version 8.2.
RESULTS
The expression of Wnt mRNAs in normal human endometrial
cells and endometrium, and endometrial carcinoma cell lines and
endometrial tumours was determined by RNAase protection
analysis.
Expression of Wnt mRNAs in normal human
endometrial cells and endometrial cells and
endometrial carcinoma cell lines
Table 1 summarizes Wnt mRNA expression in normal endometrial
epithelial (NEE) and stromal (NES) cells, and four endometrial
carcinoma cell lines: RL95-2, HEC-1-A, AN3 CA and Ishikawa.
The value indicates the ratio of Wnt gene expression to GAPDH
gene expression, where zero indicates no detectable Wnt protected
fragment after 7 days' exposure. Wnt2, 3 and 4 mRNAs were
expressed in normal endometrial cells but not endometrial carci-
noma cell lines, apart from Wnt4 in RL95-2. Wnt5a mRNA was
highly expressed in normal endometrial cells but low or even
absent in endometrial carcinoma cell lines. Wnt7a, 7b and lOb
mRNAs were absent in normal endometrial cells but expressed at
a varying degree in endometrial carcinoma cell lines. In the normal
endometrial cells, NES expressed higher levels of Wnt2, 4 and Sa
mRNAs than NEE. Wnt5a was highly expressed in NEE and NES
cells, at least twofold higher than GAPDH (result not shown). In
all assays, the negative control tRNA yielded no RNA protected
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Table 1 Expression profile of Wnt mRNAs in normal human endometrial
cells and endometrial carcinoma cell lines as determined by RNAase
protection analysis
Endometrial Wnt 2 3 4 5a 7a 7b 1Ob
cells
RL95-2 ER -ve Q 0 1.6 0.2 5.9 4.6 2.0
PR +ve
HEC-1-A ER -ve 0 0 0 0.1 5.7 0.4 0
PR +ve
AN3 CA ER-ve 0 0 0 0 0 0 1.3
PR +ve
Ishikawa ER +ve 0 0 0 0.2 0.9 0.3 0
PR+ve
NEE ER +ve 0.5 2.4 9.8 2.2 0 0 0
PR +ve
NES ER +ve 18.8 3.0 21.5 9.4 0 0 0
PR +ve
Quantified level of Wnt mRNA expression was shown as a ratio of the optical
density value of Wnt protected fragment signal to the optical density value of
GAPDH protected fragment signal of the same sample carried out in the
same assay. The results of each Wnt were obtained from the same
experiment so that a direct comparison could be made between cell lines.
ER, oestrogen receptor; PR, progestrogen receptor (Zhang et al, 1995).
fragment. A representative autoradiograph (Figure 1A) shows a
specific Wnt5a mRNA protected fragment and corresponding
GAPDH mRNA protected fragment in endometrial cells. The data
show that Wnt2, 3, 4 and 5a mRNAs were expressed at higher
levels in normal endometrial cells than endometrial carcinoma cell
lines; whereas Wnt7a, 7b and 10b mRNAs were absent in normal
endometrial cells but expressed in some endometrial carcinoma
cell lines.
Expression of Wnt mRNAs in human endometrium and
endometrial carcinoma
The Wnt mRNA expression was then assessed in intact human
endometria and endometrial tumours. Four normal human
endometrial samples were from the proliferative phase (P) and
seven fromthe secretory phase (S). Fourhuman endometrial carci-
nomas were at the superficial stage I and grade II ofthe disease in
which the tumour was confined within the uterus. Table 2 summa-
rizes Wnt mRNA expression in the normal human endometrial
tissues and endometrial carcinomas. The value indicates the ratio
A Endometrial calls B Endometrial tissues
Carcinoma Normal Normal Carcinoma
A 6 c
1 IZ Z X U)0) V 0 0 0
... _|ri - Wnt5a undigested robe
- Wnt5a protected fragment
GAPDH protected frament
Figure 1 RNAase protection analysis of Wnt5a mRNA expression in human
endometrial cells (A) and tissues (B). tRNA is a negative control. P,
proliferative phase; S, secretory phase; C, carcinoma
of Wnt gene expression to GAPDH gene expression, where zero
indicates no detectable Wnt protected fragment after 7 days' expo-
sure. Wnt2, 3, 4 and 5a mRNAs were expressed at higher levels in
normal endometrial tissues than endometrial carcinomas. There
was a statistically significant difference of Wnt4 mRNA expres-
sion between normal endometrial tissues and endometrial carci-
nomas (P = 0.03).
Since there were not enough normal endometrial samples, the
expression ofWnt7a and Wnt7b is shown for the individual cases.
The same normal endometrial tissues were used to analyse Wnt7a
and Wnt7b. One normal endometrial tissue obtained at the secre-
tory phase of the menstrual cycle produced a very strong Wnt7a
expression. The same sample also produced a detectable protected
fragment for Wnt7b. In the endometrial carcinoma, Wnt7a and
Wnt7b showed a wide range of expression overlapping with the
normal endometrium. One endometrial carcinoma sample (C4)
consistently expressed a higher level of Wnt2, 3, 4, 5a and 7a
compared with the other three endometrial carcinoma samples
(Cl-C3). WntlOb was not detected in normal endometrial tissues
and endometrial carcinomas after 7 days' exposure.
Figure lB is a representative autoradiograph showing a specific
Wnt5a mRNA protected fragment and corresponding GAPDH
mRNA protected fragment in human endometrial tissues. The data
show that Wnt2, 3, 4 and 5a exhibited a similar pattern of high
mRNA expression in normal endometrial tissues and low mRNA
expression in endometrial carcinomas.
Table 2 Quantified levels of Wnt mRNA expression in human endometria and endometrial carcinomas by RNAase protection analysis
Endometrial tissues Wnt2 Wnt 3 Wnt 4 Wnt 5a Wnt 7a Wnt 7b Wnt 1Ob
Proliferative (P) Median = 73 Median = 33 Median = 27 Median = 110.5 n = 1 n = 1 0
(n =4) Range 54-433 Range 29-52 Range 8-68 Range 62-279 2 15
Secretory (S) Median = 44 Median = 29 Median = 40 Median = 65 n = 3 n = 3
(n = 7) Range 20-170 Range 11-110 Range 29-77 Range 5-156 33,91, 1058 0, O, 3
Carcinoma (Cl) 5 3 0 3 123 98 0
Carcinoma (C2) 4 4 0 1 51 8 0
Carcinoma(C3) 2 8 0 3 4 0 0
Carcinoma (C4) 116 21 3 13 214 0 0
The Wnt mRNA expression values were obtained as a ratio of the optical density value of Wnt protected fragment signal to the optical density value of GAPDH
protected fragment signal of the same sample carried out in the same assay. P, S and C refer to proliferative phase, secretory phase and carcinoma
respectively.
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Expression of Wnt mRNAs in human endometria at
proliferative phase and secretory phase and from the
first trimester
It has been reported that ovariectomized mice exhibited a slight
reduction (20-40%) in Wnt2, Wnt4 and Wnt5b mRNA levels in
mammary gland compared with control mice (Weber-Hall et al,
1994). Therefore, the effect of ovarian hormones on Wnt mRNA
expression was investigated in human endometria during the
menstrual cycle and first trimester. Six human endometria were in
the first trimester of pregnancy. Figure 2 summarizes Wnt2, 3, 4
and 5a mRNA levels in the human endometria at three different
stages. Wnt2, 3, 4 and 5a were strongly expressed in all the tissues.
Wnt7a and Wnt7b were expressed at a low level. WntlOb was not
expressed. Figure 3 is a representative autoradiograph showing a
specific Wnt4 mRNA protected fragment and corresponding
GAPDH mRNA protected fragment in human endometria at three
different stages. Statistically, there was no significant difference in
Wnt mRNA levels in the human endometrium
1000
Wnt2, 3, 4 and 5a mRNA expression between the proliferative
phase and secretory phase of the menstrual cycle, or between
either the menstrual phase and first trimester (result not shown).
The data show that in vivo ovarian hormones had no effect on the
Wnt mRNA expression investigated.
Hormonal effect on Wnt mRNA expression in vitro in
NES and endometrial carcinoma cell lines
The effect of ovarian hormones on Wnt mRNA expression was also
investigated in vitro. After 18 h hormonal treatment at aphysiological
concentration of progesterone or oestrogen, there was no differ-
ence in the levels of Wnt2, 3, 4, 5a and 7b mRNAs between
control and progesterone and/or 1713-oestradiol-treated cells.
However, mRNA for vascular endothelial growth factor and
midkine was also studied and was induced at 18 h (Zhang et al,
1995). Figure 4 is a representative autoradiograph showing a
specific Wnt5a mRNA protected fragment and corresponding
GAPDH mRNA protected fragment in control and hormonal-
treated cells. The data show that progesterone and 17p-oestradiol
had no effect on the Wnt mRNA expression investigated in vitro,
although other hormonal-regulated genes responded.
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DISCUSSION
There is emerging evidence indicating that Wnt genes may play a
role in the genesis of human malignancy, and different Wnt genes
are involved in different tumourtypes (Huguet etal, 1994; lozzo et
al, 1995; Lejeune et al, 1995; Vider et al, 1996). We analysed Wnt
mRNA expression in human endometrium and endometrial carci-
noma cell lines derived from and in fresh tissues.
The level of Wnt4 mRNA expression was significantly higher
in normal endometrium than endometrial carcinoma, suggesting
that Wnt4 down-regulation might be important in the development
ofendometrial cancer. This down-regulation ofWnt4 mirrors that
seen following morphological transformation of C57MG cells
induced by Wntl or Wnt2 or activated neu tyrosine kinase
receptor (Olson and Papkoff, 1994). Three out ofthe fourendome-
trial carcinoma samples also expressed lower Wnt2, 3 and 5a
mRNA levels compared with normal endometrium, suggesting
I C o Z
0CL C) X0 L C.) CI) X0 CO)
w~
Wnt5aprotected fragment
GAPDH protected fragment
GAPDH
Figure 3 RNAase protection analysis of Wnt4 mRNA expression in human
endometria at proliferative phase (P), secretory phase (S) and first trimester
(T). tRNA is a negative control
Figure 4 RNAase protection analysis of Wnt5a mRNA expression in control
and hormone-treated endometrial cells. Total RNA (5 gg) was used in NES,
whereas 10 zg of total RNA was used in endometrial carcinoma cell lines. C,
untreated; +, treated for 18 h; E, 5 x 10-10 M 17pI-oestradiol; P, 5 x 10-9 M
progesterone
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these genes may also have a role in normal differentiation. In all
the known differentially expressed Wnts, this is the first case in
which a Wnt gene is down-regulated by at least sixfold in human
tumour tissues compared with normal tissues.
It was possible that the difference in Wnt mRNA expression
between normal endometrium and endometrial carcinoma was
caused by different responses to ovarian hormones. This has been
demonstrated in the mouse mammary gland in which Wnt2, 4 and
Sb were slightly down-regulated by ovarian hormones (Weber-
Hall et al, 1994). The data obtained from the endometria in the
proliferative phase and secretory phase ofthe menstrual cycle and
in the first trimester ofpregnancy in which the levels ofoestrogen
and progesterone vary dramatically, showed no variation in
mRNA expression of Wnt2, 3, 4 and Sa. Additionally, the in vitro
data show that hormonal treatment had no effect on the mRNA
expression ofthese Wnt genes plus Wnt7b.
Since the endometrium consists of a mixture of different cell
populations, largely epithelia and stroma, it is possible that the
level of Wnt mRNA expression might relate to the ratio of
epithelia to stroma, as is seen in the mouse uterus in which Wnt5a
is expressed endogenously in the uterine mesenchyme, which then
acts on the neighbouring uterine epithelia to induce expression ofa
homeobox-containing gene, Msx-J, for uterine development
(Pavlova et al, 1994). Using highly homogeneous isolated primary
normal endometrial epithelial and stromal cells (Zhang et al,
1995), Wnt2, 3, 4 and 5a mRNAs were shown to be expressed
more highly in the normal human endometrial cultures, NES and
NEE, compared with endometrial carcinoma cell lines. The
expression of Wnt2, 3, 4 and 5a genes in tum reflected the Wnt
expression seen in vivo. Therefore, the predominant cell types
isolated from normal endometrium exhibited adifferent phenotype
from the tumours. However, it could not be excluded that a minor
population of normal endometrial cells also had the same pheno-
type as the tumours, which could give rise to the differential Wnt2,
3, 4 and 5a expression between normal endometrial cells and
endometrial carcinoma cell lines.
In vitro, Wnt7a and Wnt7b were detected in endometrial carci-
noma cell lines but not in normal endometrial cultures. In compar-
ison with in vivo, both Wnt7a and Wnt7b were detected in normal
endometrial tissues and endometrial tumours. This discrepancy of
Wnt7a and Wnt7b expression in the normal endometrial cultures
and tissues could be caused by the fact that NEE and NES were
cultured cells and were maintained in an artificial environment,
and regulatory signals that determine Wnt7a and Wnt7b expres-
sion were removed. Therefore, NES and NEE may provide good
models for studying Wnt gene regulation and the factors that
perturb this normal Wnt mRNA expression pattem. The levels of
Wnt2, 4 and 5a mRNA were higher in stromal cells than epithelial
cells, whereas the level ofWnt3 mRNA was approximately equal,
suggesting the potential role of Wnt2, 4 and 5a in cell signalling
between stroma and epithelia.
In comparison with normal endometrial cells, Wnt2, 3, 4 and 5a
mRNAs were either absent or expressed at a very low level in
endometrial carcinoma cell lines. These results indicate that the
down-regulation of Wnt2, 3, 4 and 5a mRNA expression may be
associated with endometrial neoplasia. It has been demonstrated
that lowering of Wnt5a mRNA level in vitro will increase cell
branching that resembles cell migration (Huguet et al, 1995).
Therefore, the low levels ofWnt5a mRNA expression in endome-
trial carcinoma cell lines and tissues were in agreement with the
role ofWnt5a as a modulator ofcell migration (Moon et al, 1993).
This view is further strengthened by the observation that the level
of Wnt5a mRNA was extremely high in NES and NEE, and was
even higher than the GAPDH mRNA level.
Wnts are a group ofnovel growth factors that act in an autocrine
and/or paracrine manner to affect cell signalling via the cell adhe-
sion molecules (Bradley et al, 1993; Hinck et al, 1994). Little is
known about the interaction ofdifferent Wnt members or the effect
of epithelia-stroma interaction of Wnt mRNA expression.The
normal endometrial cells used in this study may be a useful model
for addressing these questions. In conclusion, the results presented
here indicate that a subset ofthe human Wnt genes (Wnt2, 3, 4 and
5a) exhibited a common differential pattern of mRNA expression
between normal and malignancy of the endometrium both in vitro
and in vivo. Six Wnt genes (Wnt2, 3, 4, 5a, 7a and 7b) were
expressed endogenously in the human endometrium, their mRNA
expression was hormonally independent and Wnt4, as well as Wnt2,
3 and 5a, gene down-regulation may be associated with endome-
trial carcinoma. The effect of down-regulation of Wnt4 has been
produced by transforming Wntl or Wnt2 in the murine mammary
epithelial cell line C57MG. We are therefore assessing whether as
yet unidentified overexpressed Wnt is inducing this effect.
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